Skip to main content
Clinical Trials/JPRN-UMIN000048463
JPRN-UMIN000048463
Completed
未知

A Prospective Study to Evaluate Effectiveness of Upadacitinib in Moderate to Severe AD with Prurigo Nodules in the Real World in Japan - ADMIRE

AbbVie GK0 sites200 target enrollmentJuly 28, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
AbbVie GK
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 28, 2022
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
AbbVie GK

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients who had prior treatment with Upadacitinib 2\.Patients who have contraindications to Upadacitinib 3\. Patients who have chronic pruritus resulting from another condition (e.g.,neuropathic disorders) than AD, prurigo nodules 4\. Patients who have prurigo nodules caused by medication, metal allergy, infection, insect bite 5\. Patients who are currently participating in interventional research or participated within 30 days (not including another post\-marketing observational study, or registry participation).

Outcomes

Primary Outcomes

Not specified

Similar Trials